2,4-thiazolidinedione has been researched along with Diabetic Angiopathies in 16 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| "Type 2 diabetes is now a global epidemic, with the number of people affected worldwide predicted to more than double to 300 million by the year 2025." | 2.42 | Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. ( Gadsby, R; Reusch, JE, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (75.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Powell, WR | 1 |
| Christiansen, CL | 1 |
| Miller, DR | 1 |
| Linz, PE | 1 |
| Lovato, LC | 1 |
| Byington, RP | 1 |
| O'Connor, PJ | 1 |
| Leiter, LA | 1 |
| Weiss, D | 1 |
| Force, RW | 1 |
| Crouse, JR | 1 |
| Ismail-Beigi, F | 1 |
| Simmons, DL | 1 |
| Papademetriou, V | 1 |
| Ginsberg, HN | 1 |
| Elam, MB | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Walker, KL | 1 |
| Walsh, DB | 1 |
| Goodney, PP | 1 |
| Connell, SA | 1 |
| Stone, DH | 1 |
| Powell, RJ | 1 |
| Rzucidlo, EM | 1 |
| Raji, A | 1 |
| Plutzky, J | 1 |
| Kudzma, DJ | 1 |
| Pathak, R | 1 |
| Afaq, A | 1 |
| Blonde, L | 1 |
| Dandona, P | 1 |
| Lawrence, I | 1 |
| Reusch, JE | 1 |
| Gadsby, R | 1 |
| Takagi, T | 1 |
| Yamamuro, A | 1 |
| Tamita, K | 1 |
| Katayama, M | 1 |
| Morioka, S | 1 |
| Hartge, MM | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Smith, U | 1 |
| Richter, B | 1 |
| Morris, AD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
7 reviews available for 2,4-thiazolidinedione and Diabetic Angiopathies
| Article | Year |
|---|---|
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies | 2002 |
Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Ag | 2002 |
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; H | 2002 |
Endothelium, inflammation, and diabetes.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Diab | 2002 |
Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic A | 2003 |
Endothelial dysfunction and its role in diabetic vascular disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
The reality of type 2 diabetes treatment today.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Patient Compliance; P | 2001 |
1 trial available for 2,4-thiazolidinedione and Diabetic Angiopathies
| Article | Year |
|---|---|
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Doub | 2014 |
8 other studies available for 2,4-thiazolidinedione and Diabetic Angiopathies
| Article | Year |
|---|---|
Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Drug Therapy, | 2019 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions.
Topics: Aged; Diabetic Angiopathies; Female; Femoral Artery; Humans; Hypoglycemic Agents; Male; Middle Aged; | 2014 |
Continuing education.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Diabetic Angiopathies; Female; Humans; Hypo | 2003 |
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Proceedings of a symposium. November 6-8, 2002, New York, New York, USA.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Met | 2003 |
Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study.
Topics: Aged; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Femal | 2005 |
Introduction: Symposium on diabetes, inflammation and cardiovascular disease.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hyperglycemia; Hypoglycemic | 2007 |
[Use of glitazones in type 2 diabetes: a critical position].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Risk Factors; Thiazol | 2001 |